EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Matching-adjusted indirect comparison of acoltremon ophthalmic solution 0.003% and cyclosporine 0.05% ophthalmic emulsion for increased tear production in patients with dry eye disease

Stephen Pflugfelder iD, Tony Okoro iD, Margaret Ainslie-Garcia iD, Anja Haltner iD, Emily K Prentiss iD, Elizabeth M Salvo-Halloran iD, Nikethana Srikanth iD, Michelle Senchyna iD, Esen K Akpek

Journal of Comparative Effectiveness Research · 2026-06 · 15 (6)

DOI: 10.57264/cer-2026-0032 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-06. Verfasst von Stephen Pflugfelder und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Baylor College of Medicine, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Cyclosporine, Dry Eye Syndromes, Tears, Ophthalmic Solutions. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Dry eye disease (DED) is a chronic, multifactorial condition arising through loss of tear film and ocular surface homeostasis. Treatment aims to restore natural tear production and normalize ocular surface homeostasis. Several prescription medications are available in the US that increase tear production in patients with DED. In the absence of head-to-head trials, this study employed a matching-adjusted indirect comparison (MAIC) approach to estimate the comparative tear production efficacy of acoltremon 0.003% and cyclosporine 0.05% for the treatment of DED. Materials & methods: MAICs were conducted for the key outcome of categorized Schirmer test score (STS), where higher values indicate greater tear production. Patient data were available for acoltremon 0.003% (from COMET-2 and COMET-3 trials) and summary level data for cyclosporine 0.05%. Populations were matched on clinically relevant variables including age, race, sex and anesthetized categorized STS. The primary analysis compared mean change from baseline (CFB) categorized STS at day 90. An exploratory analysis investigated earlier onset of tear production (day 14) attributed to acoltremon 0.003% compared with the earliest available data (day 90) for cyclosporine 0.05%.

Results

After all adjustments, a greater mean CFB categorized STS was observed for acoltremon 0.003% compared with cyclosporine 0.05% (mean difference [MD]: 1.62 categories, 95% CI: 1.42–1.83, p < 0.001) at day 90. The exploratory analysis also demonstrated a greater mean CFB categorized STS for day 14 acoltremon 0.003% compared with day 90 cyclosporine 0.05% (MD: 1.62 categories, 95% CI: 1.42–1.82, p < 0.001).

Conclusion

Our findings suggest that acoltremon 0.003% may provide a greater increase in tear production relative to cyclosporine 0,05% at day 90, with exploratory findings suggesting similar results at day 14. As this was an unanchored MAIC, results may be influenced by residual confounding from unmeasured differences between trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclosporineDry Eye SyndromesTearsOphthalmic SolutionsHumansFemaleMaleMiddle AgedAdultAgedEmulsionsCyclohexenes

Stichwörter der Autor:innen

TRPM8 receptor agonistacoltremoncyclosporine 0.05%dry eye diseasematching-adjusted indirect comparison

Substanzen

CyclosporineOphthalmic SolutionsEmulsionsacoltremonCyclohexenes

Autor:innen und Institutionen

  • Department of Ophthalmology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Alcon, Fort Worth, TX 76134-2001, USA.
  • EVERSANA, Victoria, BC, V8W 2E1, Canada.
  • EVERSANA, New York, NY 10018, USA.
  • EVERSANA, Chicago, IL 60601, USA.
  • Foster Center for Ocular Immunology and Inflammation, Duke University School of Medicine, Durham, NC 27705, USA.

ORCID-Profile: Stephen Pflugfelder, Tony Okoro, Margaret Ainslie-Garcia, Anja Haltner, Emily K Prentiss, Elizabeth M Salvo-Halloran, Nikethana Srikanth, Michelle Senchyna

Zitieren

APA

Pflugfelder, S., Okoro, T., Ainslie-Garcia, M., Haltner, A., Prentiss, E. K., Salvo-Halloran, E. M., Srikanth, N., Senchyna, M., & Akpek, E. K. (2026). Matching-adjusted indirect comparison of acoltremon ophthalmic solution 0.003% and cyclosporine 0.05% ophthalmic emulsion for increased tear production in patients with dry eye disease. Journal of Comparative Effectiveness Research, 15(6). https://doi.org/10.57264/cer-2026-0032

Vancouver

Pflugfelder S, Okoro T, Ainslie-Garcia M, Haltner A, Prentiss EK, Salvo-Halloran EM, et al. Matching-adjusted indirect comparison of acoltremon ophthalmic solution 0.003% and cyclosporine 0.05% ophthalmic emulsion for increased tear production in patients with dry eye disease. Journal of Comparative Effectiveness Research. 2026;15(6). doi:10.57264/cer-2026-0032

BibTeX
@article{Pflugfelder2026,
  author = {Pflugfelder, Stephen and Okoro, Tony and Ainslie-Garcia, Margaret and Haltner, Anja and Prentiss, Emily K and Salvo-Halloran, Elizabeth M and Srikanth, Nikethana and Senchyna, Michelle and Akpek, Esen K},
  title = {Matching-adjusted indirect comparison of acoltremon ophthalmic solution 0.003% and cyclosporine 0.05% ophthalmic emulsion for increased tear production in patients with dry eye disease},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  volume = {15},
  number = {6},
  doi = {10.57264/cer-2026-0032}
}
Kostenlos starten →